m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition

By sjmartinez • April 16, 2023

Benavides-Serrato A, Saunders JT, Kumar S, Holmes B, Benavides KE, Bashir MT, Nishimura RN, Gera J. m⁶A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition. Cancer Lett. 2023 Apr 13:216178. doi: 10.1016/j.canlet.2023.216178. Epub ahead of print. PMID: 37061119.

Tags: Drug resistance, Glioblastoma, Hematology/Oncology, IRES, ITAF, mTOR inhibitors, N(6)-methyladenosine modification, Publications, Veterans Administration

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database

Bachet JB, de Gramont A, Raeisi M, Rakez M, Goldberg RM, Tebbutt NC, Van Cutsem E, Haller DG, Hecht JR, Mayer RJ, Lichtman SM, Benson[...]

Diagnostic Challenges in a Case of Hemophagocytic Lymphohistiocytosis Likely Induced by Coxiella burnetii

Tai JW, Wu P. Diagnostic Challenges in a Case of Hemophagocytic Lymphohistiocytosis Likely Induced by Coxiella burnetii. Cureus. 2025 Apr 2;17(4):e81634. doi: 10.7759/cureus.81634. PMID: 40322410;[...]

Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotyping

Cavanaugh D, Holt SK, Dwyer E, Petersen E, Gore JL, Schade GR, Grivas P, Hsieh AC, Lee JK, Montgomery B, Schweizer MT, Yezefski T, Yu[...]